Therapeutic drug monitoring in tuberculosis: practical application for physicians

Clinical Infectious Diseases

Volumn 64, Issue 1, 2017, Pages 104-105

  Alffenaar, Jan Willem C ^a   Tiberi, Simon ^c   Verbeeck, Roger K ^d   Heysell, Scott K ^e   Grobusch, Martin P ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d UNIVERSITY OF NAMIBIA   (Namibia)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

BACTERIAL LOAD; BACTERICIDAL ACTIVITY; DRIED BLOOD SPOT TESTING; DRUG COST; DRUG EXPOSURE; DRUG MONITORING; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS; COMMUNICABLE DISEASE; ORGANIZATION; PUBLIC HEALTH SERVICE; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMMUNICABLE DISEASES; DRUG MONITORING; HUMANS; SOCIETIES; TUBERCULOSIS; UNITED STATES;

EID: 85015205892     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw677     Document Type: Letter

References (10)

1. Nahid P, Dorman S, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63:e147-95.
2. van der Burgt EP, Sturkenboom MGG, Bolhuis MS, et al. End TB with precision treatment! Eur Respir J 2016; 47:680-2.
3. Lange C, Abubakar I, Alffenaar J-WC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement. Eur Respir J 2014; 44:23-63.
4. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
5. Donald PR, Sirgel FA, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004; 39:1425-30.
6. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogeneticsbased therapy. Eur J Clin Pharmacol 2013; 69:1091-101.
7. Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol 2016; 12:509-21.
8. Heysell SK, Pholwat S, Mpagama SG, et al. Sensititre MycoTB plate compared to BactecMGIT 960 for firstand second-line antituberculosis drug susceptibility testing in Tanzania: A call to operationalize MICs. Antimicrob Agents Chemother 2015; 59:7104-8.
9. Vu DH, Alffenaar JWC, Edelbroek PM, Brouwers JRBJ, Uges DRA. Dried blood spots: A new tool for tuberculosis treatment optimization. Curr Pharm Des 2011; 17:2931-9.
10. Ghimire S, Bolhuis MS, Sturkenboom MGG, et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur Respir J 2016; 47:1867-9.